Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials

Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials

Abstract Background Conversion from calcineurin inhibitor (CNI) therapy to a mammalian target of rapamycin (mTOR) inhibitor following kidney transplantation may help to preserve graft function. Data are sparse, however, concerning the impact of conversion on posttransplant diabetes mellitus (PTDM) o...

Full description

Bibliographic Details
Main Authors: Claudia Sommerer, Oliver Witzke, Frank Lehner, Wolfgang Arns, Petra Reinke, Ute Eisenberger, Bruno Vogt, Katharina Heller, Johannes Jacobi, Markus Guba, Rolf Stahl, Ingeborg A. Hauser, Volker Kliem, Rudolf P. Wüthrich, Anja Mühlfeld, Barbara Suwelack, Michael Duerr, Eva-Maria Paulus, Martin Zeier, Martina Porstner, Klemens Budde, on behalf of the ZEUS and HERAKLES study investigators
Format: Article
Language:English
Published: BMC 2018-09-01
Series:BMC Nephrology
Subjects:
Diabetes
Everolimus
Kidney transplantation
TOR inhibitor
PTDM
Post-transplant
Online Access:http://link.springer.com/article/10.1186/s12882-018-1031-1

Internet

http://link.springer.com/article/10.1186/s12882-018-1031-1

Similar Items